TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a PGA Response of Clear or Almost Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean ratios (GMRs) as determined by HI assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with an HI titer ≥1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: P-wave Duration and Dispersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device Revision/Removal
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Diameter of Radial Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee pain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes with clear corneal incision/suture leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Protection against HCV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Expression of HLA-DR and CD38+ markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of oxidative stress markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Who Achieve a PASI75 Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Subjects Who Achieve a PGA Clear or Almost Clear Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in distance of asymptomatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in distance of claudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Plasma Estradiol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline of Tricuspid Annular Plane Systolic Excursion (TAPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline of Six Minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Plasma NT-proBNP Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Grade 2 antrum
Endpoint domain: Adverse events/effects
Primary endpoint: Microvascular perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial activation and damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Erythema Assessment (CEA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Volume of uterine leiomyomata
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance-free days after release from prison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of substance use after release from prison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of Crow's Feet Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: treatment outcome of erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Antibiotic sensitivity patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of Response (DoR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: LDH/albumin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in catastrophizing cognitions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effectiveness of biomarkers to diagnose diabetic foot osteomyelitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of biomarkers to differentiate osteomyelitis from deep soft tissue infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phantom Limb Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Baseline Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality from COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Change of heart rate between 1st and 2nd 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sit-to-stand time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit-to-stand velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit-to-stand power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lipid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: concentration of ceftazidime and cefazolin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family Functioning: General Functioning
Endpoint domain: Life impact
Endpoint subdomain: General outcomes
Primary endpoint: Youth mental health: Child Behavior Checklist(CBCL/YSR), Total Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver mental health: Total Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Assisted Epistaxis Severity Scale (aESS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface area of the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Posttraumatic Stress Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Septal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anogenital Distance (AGD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Villalta Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum uric acid (SUA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Local and systemic signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Local Recurrence of Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Percent change in direct LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the frequency of ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Society Scoring
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUCτ,ss / Cmax of pregabalin and thioctic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset and duration of lid and globe akinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Had Not Relapsed at Any Time in the Trial
Endpoint domain: Mortality/survival
Primary endpoint: Plasma levels of paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Discomfort in Chewing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Immune response to influenza virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response to influenza vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With HBeAg-Positive CHB Achieving Sustained Immune Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With HBeAg-Negative CHB Achieving Sustained Immune Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Toxicities and Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge, confidence and skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety events (ADRs and SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Lower extremity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average total time of Awake Fiberoptic Orotracheal Intubation (AFOI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of one-time intubation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Access to abortion care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Intention to provide abortion service
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Ischemia reperfusion injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 minute Pegboard and Ring Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of endoscopic sphincterotomy successfully performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With IP Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment Emergent Solicited and Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Motor Milestones Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Death or Permanent Ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Presence/absence of subclinical keratoconus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined total mortality
Endpoint domain: Mortality/survival
Primary endpoint: First event of non-fatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospital admission for new or worsened heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uncorrected Visual Acuity of 20/20 or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of microcephaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of Positive Urine Tests at 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Emergency Department Overdose(s) at 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Engaged in Medication Assisted Therapy (MAT) Within 180 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUClast of rosuvastatin and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of rosuvastatin and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C5 palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change on pain sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of rehospitalization for acute heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of day-hospital or at-home IV diuretics injection for acute HF
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immunogenicity to vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of TGF-β1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Curve for Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving Stable Dose of EMBEDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spherical Equivalent of Cycloplegic Autorefraction (SECAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: PAP-specific IFNγ-secreting CD8+ T cells generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Baby discharged alive
Endpoint domain: Mortality/survival
Primary endpoint: Alive at 6 months if hospitalized
Endpoint domain: Mortality/survival
Primary endpoint: Change of Blepharitis Symptoms Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Symptoms and Signs Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Narcotic Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analog Scale (VAS) Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Restored CVAD Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Duration of Hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: readmission within 30 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain control, according to a scale from 0-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levine Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Characterized by Abnormal or Negative Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases of menstruation, pregnancy and labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chewing side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for an Increase in Study Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of Emergence delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative power of each brain waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in H-line, Dynamic MRI measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in M-line, Dynamic MRI measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in O classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and Microbiological Improvement in nails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants showing up for HIV sero test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in motor cortex excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in spontaneous electrical brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maternal and cord blood serum etonogestrel concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Digestive symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1C (A1C) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived Fitness to Drive
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunogenicity measured by 4-fold rise in HAI titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gallbladder and Liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Log Reduction of Bacterial Flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to drug discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: de novo urge urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: average prevalence of ocular chlamydia infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Preoperative cervical width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID19 clinical scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric accommodation (intragastric pressure drop)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Conversion of breech to vertex presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Drug use pattern
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of reduction in plasma uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quick Inventory of Depressive Symptomatology (QIDS-SR16)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mechanical complications of acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health-related quality of life (HRQoL) after transplantation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ability of CopiOs to fill bone void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients without an adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration versus time curve from zero to infinity (AUC) of finerenone in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve from zero to infinity of unbound finerenone (AUCu) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration (Cmax) of finerenone in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration of unbound finerenone (Cmax,u) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to deliver intensive inpatient physical rehabilitation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of treatment and non-treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Risperidone area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG interval change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total serum iron pharmakokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose of ruxolitinib phosphate
Endpoint domain: Adverse events/effects
Primary endpoint: Ultrasound Examination of Number of Follicles and Ovarian Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Menstrual Regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes